CATX AMEX
Perspective Therapeutics, Inc.
1W: +0.5%
1M: -17.6%
3M: -31.3%
YTD: +39.1%
1Y: +37.1%
3Y: -23.9%
5Y: -49.7%
$3.98
+0.11 (+2.84%)
Weekly Expected Move ±9.7%
$3
$3
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (32)
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Short Interest Update
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics Q1 EPS Boosted by HC Wainwright
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of “Buy” from Analysts
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 4.4% – Here’s What Happened
Perspective Therapeutics Non-GAAP EPS of -$1.40 misses by $0.20, revenue of $0.9M misses by $0.17M
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Here are the major earnings after the close Monday
Earnings Scheduled For March 16, 2026
Perspective Therapeutics Q4 2025 Earnings Preview
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell?
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages
Perspective Therapeutics to Participate in Upcoming December Conferences